Warnings
A, No Usar
Påvist Troparil - WIN35,065, Impurezas. Placering: Barcelona, Spanien. Dato: 2022-03-14. Kilde: energycontrol.org.
A, No Usar-pille — Barcelona, Spanien — 2022-03-14
- Detected
- Troparil - WIN35,065, Impurezas
- Expected
- Unknown
- Logo
- A, No Usar
- Color
- white
- Location
- Barcelona, Spain
- Date
- 2022-03-14
- Source
- energycontrol.org
- Media
- No image
Detected Substances
- Troparil - WIN35,065
- Impurezas
Expected vs Detected
No expected substance was recorded for this sample.
Detected result: Troparil - WIN35,065, Impurezas
Sample Details
No additional sample descriptors available.
Testing Context
- Location: Barcelona, Spanien
- Date tested: 2022-03-14
- Source: energycontrol.org
Harm Reduction
- Similar-looking pills can contain different substances or strengths.
- Use drug checking services when available.
- Start low and avoid assuming a logo identifies the contents.
SampleDNA Beta
68 tilsluttede advarsler · Lær mere om almindelige urenheder.
- Troparil - WIN35,065Registreret
- ImpurezasRegistreret
Relaterede prøver og kombinationer
No Usar logo
68 prøver · Nuværende resultat
Det samme logo vises i relaterede prøveresultater for lægemiddelkontrol.
- MDMA A, No Usar · Granada, Spanien · 2025-02-26
- 2C-B A, No Usar · Córdoba, Spanien · 2022-11-10
- MDMA A, No Usar · Huesca, Spanien · 2022-07-30
- Unknown A, No Usar · Barcelona, Spanien · 2022-05-17
- MDMA No Usar · Barcelona, Spanien · 2021-12-14
- MDMA No Usar · Múrcia, Spanien · 2021-12-14
A logo
8 prøver · Nuværende resultat
Det samme logo vises i relaterede prøveresultater for lægemiddelkontrol.
- Cocaine + Phenacetin + Benzoylecgonine A · Cardiff (CF24), Wales · 2026-06-19
- MDMA A, No Usar · Granada, Spanien · 2025-02-26
- 2C-B A, No Usar · Córdoba, Spanien · 2022-11-10
- MDMA A, No Usar · Huesca, Spanien · 2022-07-30
- Unknown A, No Usar · Barcelona, Spanien · 2022-05-17
- Unknown A, No Usar · Guadalajara, Spanien · 2020-07-23
SampleDNA-udforsker
Links
This static page is intended as the readable export baseline for crawler and low-capability delivery.